Evidence map›Paper›PMID 41064997›Full record

ReviewBioanalysis2025

CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples.

Xiaoqing Chen, Qiaoyuan Ye, Qingle Liang, Jiahui Li, Yumei Huang, Qiyuan Xia, Jianrong Xiao, Chenyu Liao, Cia-Hin Lau, Haibao Zhu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoqing ChenDepartment of Biology, College of Science, Shantou University, Shantou, Guangdong, China.
Qiaoyuan YeDepartment of Dermatology and Venereology, liaobu Hospital of Dong Guang City, Dongguang, Guangdong, China.
Qingle LiangDepartment of Clinical Laboratory Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.
Jiahui LiDepartment of Biology, College of Science, Shantou University, Shantou, Guangdong, China.
Yumei HuangDepartment of Biology, College of Science, Shantou University, Shantou, Guangdong, China.
Qiyuan XiaDepartment of Biology, College of Science, Shantou University, Shantou, Guangdong, China.
Jianrong XiaoDepartment of Biology, College of Science, Shantou University, Shantou, Guangdong, China.
Chenyu LiaoDepartment of Biology, College of Science, Shantou University, Shantou, Guangdong, China.
Cia-Hin LauDepartment of Biology, College of Science, Shantou University, Shantou, Guangdong, China.
Haibao ZhuDepartment of Biology, College of Science, Shantou University, Shantou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-associated genetic markers are useful for early cancer screening, diagnosis, and treatment monitoring. However, traditional detection methods are complex in operation procedures, time-consuming, and the equipment costs are expensive. CRISPR/Cas systems are becoming emerging detection tools for tumor detection due to their programmability, rapid reaction, high targeting specificity, and the ability to amplify the signals. CRISPR/Cas has made breakthroughs in the detection of tumor-associated genetic materials including gene mutations, DNA methylation, miRNA, lncRNA, and circRNA detection. Herein, we critically discuss these advancements and describe the key concepts of each CRISPR/Cas system for detecting tumor-associated genetic materials. The significance of these tumor-associated genetic materials in cancer diagnosis and prognosis is highlighted.

Indexed as

CRISPR-Cas SystemsBiomarkers, TumorHumansMicroRNAsMutationBiomarkers, TumorMicroRNAsCancer detectionCas12aCas13aCRISPRtumor biomarker

Identifiers

PMID41064997
PMCPMC12667656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.